Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

(2023) J.M. Versluis et al.   ANNALS OF ONCOLOGY

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

(2023) Irene L.M. Reijers et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

(2023) Sapna P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

(2022) Alexander C. J. van Akkooi et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy

(2022) Maria I. Carlo et al.   EUROPEAN UROLOGY

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

(2022) Inês Pires da Silva et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

(2022) Jason J Luke et al.   LANCET

Optimal systemic therapy for high-risk resectable melanoma

(2022) Alexander M. M. Eggermont et al.   Nature Reviews Clinical Oncology

Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.

(2022) Judith M. Versluis et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

(2022) Claus Garbe et al.   JOURNAL OF CLINICAL ONCOLOGY

NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.

(2022) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

(2022) Reinhard Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.

(2022) Alexander M. Menzies et al.   JOURNAL OF CLINICAL ONCOLOGY

The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.

(2022) Minke W. Lucas et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).

(2022) Kari Lynn Kendra et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

(2022) Irene L. M. Reijers et al.   NATURE MEDICINE

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

(2022) G.V. Long et al.   ANNALS OF ONCOLOGY

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

(2022) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

(2022) Elisabeth Livingstone et al.   LANCET

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

(2022) Georgina V Long et al.   LANCET ONCOLOGY

Neoadjuvant relatlimab and nivolumab in resectable melanoma

(2022) Rodabe N. Amaria et al.   NATURE

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

(2022) Rebecca C. Simpson et al.   NATURE MEDICINE

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

(2022) Neil D. Gross et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety

(2022) Lan Shao et al.   Journal of Thoracic Disease

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

(2022) Joel Ho et al.   Frontiers in Oncology

High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy

(2022) Laurent Dercle et al.   EUROPEAN JOURNAL OF CANCER

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

(2021) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

(2021) R.V. Rawson et al.   ANNALS OF ONCOLOGY

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

(2021) Paolo A. Ascierto et al.   CLINICAL CANCER RESEARCH

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

(2021) R. Dummer et al.   NATURE MEDICINE

The Role of Immune Checkpoint Blockade in Uveal Melanoma

(2020) Anja Wessely et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016

(2020) Juliana Berk-Krauss et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Lisa Zimmer et al.   LANCET

Learning from clinical trials of neoadjuvant checkpoint blockade

(2020) Judith M. Versluis et al.   NATURE MEDICINE

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

(2020) M.T. Tetzlaff et al.   ANNALS OF ONCOLOGY

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

(2020) Alexander M. M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

(2020) Paolo A Ascierto et al.   LANCET ONCOLOGY

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

(2020) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

(2020) Pier Francesco Ferrucci et al.   Journal for ImmunoTherapy of Cancer

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy

(2019) Martine Bloemendal et al.   ANNALS OF SURGICAL ONCOLOGY

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

(2019) O Hamid et al.   ANNALS OF ONCOLOGY

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients

(2019) Rumana N. Hussain et al.   MELANOMA RESEARCH

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma

(2019) Nirmish Singla et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy

(2019) Ines Pires da Silva et al.   CANCER

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

(2019) Tuba N. Gide et al.   OncoImmunology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

(2018) Rodabe N Amaria et al.   LANCET ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH